Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T19:45:16.220Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolism, anticholinergic effects, and therapeutic outcome of desmethylimipramine in depressive illness

Published online by Cambridge University Press:  09 July 2009

D. C. Watt ,
J. L. Crammer  and
A. Elkes
D. C. Watt
Affiliation:
From St. John's Hospital, Stone, Aylesbury, Bucks.
J. L. Crammer
Affiliation:
From St. John's Hospital, Stone, Aylesbury, Bucks.
A. Elkes
Affiliation:
From St. John's Hospital, Stone, Aylesbury, Bucks.
Get access Rights & Permissions [Opens in a new window]

Synopsis

In order to test two theories of the mode of action of imipramine 58 depressive patients were treated at two dosage levels with desmethylimipramine (DMI), its active metabolite. Clinical judgments were used to distinguish therapeutic responders from non-responders, who showed clear differences in depressive rating scales and body weight changes. Measurements of urinary output of DMI, of salivation, and of the incidence of side-effects were compared in responders and non-responders: no differences appeared between the two groups. It is concluded that the therapeutic effect of imipramine does not depend on either its anticholinergic or other action revealed by the common side-effects, and that variability of response cannot be accounted for by differences in the rate of metabolism of DMI.

Type
Research Article
Information
Psychological Medicine , Volume 2 , Issue 4 , November 1972 , pp. 397 - 405
Copyright
Copyright © Cambridge University Press 1972

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Angst, J. (1961). A clinical analysis of the effects of Tofranil in depression. Psychopharmacologia, 2, 381–407.CrossRefGoogle ScholarPubMed
Åsberg, M., Cronholm, B., Sjöqvist, F., and Tuck, D. (1970). Correlation of subjective side effects with plasma concentrations of nortriptyline. British Medical Journal, 4, 18–21.CrossRefGoogle ScholarPubMed
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571.CrossRefGoogle ScholarPubMed
Bente, D., Hoffmeister, F., Kreiskott, H., and Wirth, W. (1965). Zur Frage pharmakologisch-klinischer Wirkungs-korrelate bei zentral dampfenden psychotropen Pharmaka Neuro-psychopharmacology IV, pp. 392–395. Elsevier: Amsterdam.Google Scholar
Biel, J. H., Nuhfer, P. A., Hoya, W. K., Leiser, H. A., and Abood, L. G. (1962). Cholinergic blockade as an approach to the development of new psychotropic agents. Annals of the New York Academy of Sciences, 96, 251–262.CrossRefGoogle Scholar
Blackwell, B., and Shepherd, M. (1967). Early evaluation of psychotropic drugs in man. Lancet, 2, 819–822.CrossRefGoogle ScholarPubMed
Brimblecombe, R. W., and Green, D. M. (1967). Central effects of imipramine-like antidepressants in relation to their peripheral anticholinergic activity. international Journal of Neuropharmacology, 6, 133–142.CrossRefGoogle Scholar
Busfield, B. L., and Wechsler, H. (1963). Salivation as an index of higher nervous activity in diseases with prominent psychopathology. Pp. 346–356. In Psychopharmacological Methods. Medical State Publishing House: Prague; Pergamon: Oxford.Google Scholar
Cairncross, K. D., Gershon, S., and Gust, I. D. (1963). Some aspects of the mode of action of imipramine. Journal of Neuropsychiatry, 4, 224–231.Google ScholarPubMed
Crammer, J. L., and Elkes, A. (1969). Body weight in depression and the effect of desmethyl-imipramine. In Proceedings of the VI International Congress of the C.I.N.P. Excerpta Medica International Congress Series No. 180. Excerpta Medica: Amsterdam.Google Scholar
Crammer, J. L., and Scott, B. (1968). The excretion of desmethylimipramine and its metabolites in depressive patients. In Proceedings of the Fourth World Congress of Psychiatry, Madrid, 1966. International Congress Series No. 150. Part 3. pp. 1942–1944. Excerpta Medica Foundation: Amsterdam.Google Scholar
Crammer, J. L., Scott, B., Woods, H., and Rolfe, B. (1968). Metabolism of 14C-imipramine. 1. Excretion in the rat and in man. Psychopharmacologia, 12, 263–277.CrossRefGoogle Scholar
Davies, B., and Palmai, G. (1964). Salivary and blood pressure responses to methacholine in depressive illness. British Journal of Psychiatry, 110, 594–598.CrossRefGoogle ScholarPubMed
Dingell, J. V., Sulser, F., and Gillette, J. R. (1964). Species differences in the metabolism of imipramine and desmethylimipramine (DMI). Journal of Pharmacology and Experimental Therapeutics, 143, 14–22.Google Scholar
Duvoisir, R. C. (1967). Cholinergic—anticholinergic antagonism in Parkinsonism. Archives of Neurology, 17, 124–136CrossRefGoogle Scholar
Eble, J. N., Gowdey, C. W., and Vane, J. R. (1971). Blood concentration of noradrenaline in the dog after intravenous administration and the effects of desipramine. Nature, 231, 181–182.CrossRefGoogle ScholarPubMed
Goodman, L. S., and Gilman, A. Z. (ed.) (1970). The Pharmacological Basis of Therapeutics, p. 528. 4th ed.Macmillan: New York.Google Scholar
Gyermek, L. (1966). Effects of imipramine-like antidepressant agents on the autonomic nervous system. In Anti-depressant Drugs of the Non-MAO Type, pp. 41–62. Edited by Efron, D. H. and Kety, S. S.. U.S. Government Printing Office: Washington.Google Scholar
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.Google ScholarPubMed
Hammer, W., and Sjöqvist, F. (1967). Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sciences, 6, 1895–1903.CrossRefGoogle ScholarPubMed
Halliwell, G., Quinton, R. M., and Williams, F. E. (1964). A comparison of imipramine/chlorpromazine and related drugs in various tests involving autonomie functions and antagonism of reserpine. British Journal of Pharmacology, 23, 330–350.Google Scholar
Lapin, I. P. (1966). Antidepressants of the imipramine group. Transactions of the V.M. Bekhterev Leningrad Institute of Psychopharmacology, 34, 31–50. English pr´cis: Psychopharmacology (Abstracts 71374), 1968,7.Google Scholar
Liddell, J. (1968). Cholinesterase variants and suxamethonium apnoea. Proceedings of the Royal Society of Medicine, 61, 168–170.CrossRefGoogle ScholarPubMed
Mandell, A. J., Markham, C. H., Tallman, F. F., and Mandell, M. P. (1962). Motivation and ability to move. American Journal of Psychiatry, 119, 544–549.CrossRefGoogle Scholar
Medical Research Council (1965). Clinical trial of the treatment of depressive illness. Report by Clinical Psychiatry Committee. British Medical Journal, 1, 881–886.CrossRefGoogle Scholar
Montgomery, R. B., Singer, G., Purcell, A. T., Narbeth, J., and Bolt, A. G. (1971). The effects of intrahypothalamic injections of desmethylimipramine on food and water intake of the rat. Psychopharmacologia, 19, 81–86.CrossRefGoogle ScholarPubMed
Price-Evans, D. A. (1965). Individual variations of drug metabolism as a factor in drug toxicity. Annals of the New York Academy of Sciences, 123, 178–187.CrossRefGoogle Scholar
Shepherd, M. (1971). A critical review of clinical drugs trials. In Depression in the 1970's. Excerpta Medica International Congress Series No. 239. Excerpta Medica: Amsterdam.Google Scholar
Sigg, E. B., Soffer, L., and Gyermek, L. (1963). Influence of imipramine and related psychoactive agents on the effect of 5-hydroxytryptamine and catecholamines on the cat nictitating membrane. Journal of Pharmacology and Experimental Therapeutics, 142, 13–20.Google ScholarPubMed